/Catalent%20Inc_%20on%20phone%20and%20website-by%20T_Schneider%20via%20Shutterstock.jpg)
Catalent, Inc. (CTLT), headquartered in Somerset, New Jersey, enables pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients worldwide. Valued at $10.62 billion by market cap, the company has expertise in development sciences, delivery technologies, and multi-modality manufacturing. It is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. The leading global CDMO is expected to announce its fiscal fourth-quarter earnings for 2024 on Tuesday, Sep. 3.
Ahead of the event, analysts expect CTLT to report a profit of $0.44 per share on a diluted basis, up 388.9% from $0.09 per share in the year-ago quarter. The company missed the consensus estimates in three of the last four quarters while beating on another occasion.